Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Stopped early · Phase 1

Conditions studied: Glioblastoma, MGMT-Unmethylated Glioblastoma

In brief

This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase (MGMT) promoter unmethylated glioblastoma (GBM). Drugs used in chemotherapy, such as microtubule-targeted agent BAL101553, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving microtubule-targeted agent BAL101553 and radiation therapy may work better in treating patients with GBM.

Key facts

Study ID: NCT03250299
Run by: Basilea Pharmaceutica
People needed: 26
Starts: 2017-12-15
Expected to finish: 2022-08-24
Last updated by the study team: 2024-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

UAB Comprehensive Cancer Center — Birmingham, Alabama, United States
Johns Hopkins University — Baltimore, Maryland, United States
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
Henry Ford Hospital — Detroit, Michigan, United States
Wake Forest University Comprehensive Cancer Center — Winston-Salem, North Carolina, United States
Cleveland Clinic Taussig Cancer Center — Cleveland, Ohio, United States
Abrams Cancer Center of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.